1 Scientometric analysis of mTOR signaling pathway in liver disease.

2 The global scientific research response to the public health emergency of Zika virus infection.

3 Activated L-Arginine/Nitric Oxide Pathway in Pediatric Cystic Fibrosis and Its Association with Pancreatic Insufficiency, Liver Involvement and Nourishment: An Overview and New Results

4 the effects of melatonin in patients with nonalcoholic fatty liver disease: a randomized controlled trial

5 the hop constituent xanthohumol exhibits hepatoprotective effects and inhibits the activation of hepatic stellate cells at different levels

6 case report of cirrhosis following yttrium-90 radioembolization for pancreatic neuroendocrine liver metastases

7 Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo-controlled, double-blind clinical trial.

8 The Role of Oxidative Stress and Antioxidants in Liver Diseases

9 Circ_1639 induces cells inflammation responses by sponging miR-122 and regulating TNFRSF13C expression in alcoholic liver disease.

10 Suboptimal treatment of dyslipidemia in patients with nonalcoholic fatty liver disease.

11 A Mediterranean Diet Rich in Extra-Virgin Olive Oil Is Associated with a Reduced Prevalence of Nonalcoholic Fatty Liver Disease in Older Individuals at High Cardiovascular Risk.

12 Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years

13 Echinocandins for management of invasive candidiasis in patients with liver disease and liver transplantation

14 L-Ornithine L-Aspartate for the Treatment of Sarcopenia in Chronic Liver Disease: The Taming of a Vicious Cycle

15 Echinocandins for management of invasive candidiasis in patients with liver disease and liver transplantation

16 Evaluation of diffusion kurtosis imaging in stratification of nonalcoholic fatty liver disease and early diagnosis of nonalcoholic steatohepatitis in a rabbit model.

17 Augmented intelligence with natural language processing applied to electronic health records for identifying patients with non-alcoholic fatty liver disease at risk for disease progression.

18 Liver Ultrasound Patterns in Children with Cystic Fibrosis Correlate with Noninvasive Tests of Liver Disease

19 Association Between Nonalcoholic Fatty Liver Disease and Severe Male Reproductive Organ Impairment (Germinal Epithelial Loss): Study on a Mouse Model and on Human Patients

20 Prevalence of chronic liver disease among young/middle-aged adults in Northern Italy: role of hepatitis B and hepatitis C virus infection by age, sex, ethnicity.

21 Management of patients with EPP related progressive liver disease.

22 Liver Stiffness Assessed by Ultrasound Shear Wave Elastography from General Electric Accurately Predicts Clinically Significant Portal Hypertension in Patients with Advanced Chronic Liver Disease.

23 [Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].

24 Wisteria floribunda agglutinin-positive mac-2 binding protein as an age-independent fibrosis marker in nonalcoholic fatty liver disease

25 Inhibition of lncRNA HULC improves hepatic fibrosis and hepatocyte apoptosis by inhibiting the MAPK signaling pathway in rats with nonalcoholic fatty liver disease

26 Erratum: Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease (Cell Metabolism (2017) 25(5) (1054–1062.e5), (S1550413117302061), (10.1016/j.cmet.2017.04.001))

27 Neutrophil-to-lymphocyte ratio is independently associated with inflammatory activity and fibrosis grade in nonalcoholic fatty liver disease

28 Validation Study of Elastographies in Patients With Nonalcoholic Fatty Liver Disease for Detecting Liver Fibrosis

29 The Role of Lipid and Lipoprotein Metabolism in Non‐Alcoholic Fatty Liver Disease

30 Curcumin: Reintroduced Therapeutic Agent from Traditional Medicine for Alcoholic Liver Disease

31 Raw Bowl Tea (Tuocha) Polyphenol Prevention of Nonalcoholic Fatty Liver Disease by Regulating Intestinal Function in Mice.

32 BURDEN OF ALCOHOL IN PATIENTS WITH ALCOHOLIC LIVER DISEASE [ALD] AND THEIR FAMILIES IN ODISHA

33 TRIB1 rs17321515 gene polymorphism increases the risk of coronary heart disease in general population and non-alcoholic fatty liver disease patients in Chinese Han population.

34 [Fatal liver disease due to amoxicillin-clavulanic acid in nonagenarian patient].

35 Sleep Disruption and Daytime Sleepiness Correlating with Disease Severity and Insulin Resistance in Non-Alcoholic Fatty Liver Disease: A Comparison with Healthy Controls.

36 Hepatic Mitochondrial Defects in a Nonalcoholic Fatty Liver Disease Mouse Model Are Associated with Increased Degradation of Oxidative Phosphorylation Subunits.

37 Twitter As a Noninvasive Bio-Marker for Trends in Liver Disease.

38 Hepatitis B virus (HBV) infection and liver disease after allogeneic bone marrow transplantation: a report of 30 cases.

39 Mediterranean Diet and Multi-Ingredient-Based Interventions for the Management of Non-Alcoholic Fatty Liver Disease

40 Nonalcoholic Fatty Liver Disease in South Asia.

41 Whole Grain Consumption and Its Effects on Hepatic Steatosis and Liver Enzymes in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial.

42 Leptin/adiponectin ratio correlates with hepatic steatosis but not arterial stiffness in nonalcoholic fatty liver disease in Japanese population

43 Intermediary effect of inflammation on the association between dietary patterns and non-alcoholic fatty liver disease.

44 Lifestyle Intervention Framework for Obese Patients with Non-alcoholic Fatty Liver Disease - a Tool for Health Professionals in Resource Constraint Settings.

45 Could phthalates exposure contribute to the development of metabolic syndrome and liver disease in humans?

46 Magnesium and liver disease.

47 Fat and sugar—a dangerous duet. A comparative review on metabolic remodeling in rodent models of nonalcoholic fatty liver disease

48 Endoscopic bariatric and metabolic therapies for non-alcoholic fatty liver disease

49 Unacceptable failures: the final report of the Lancet Commission into liver disease in the UK.

50 NLRP3 inhibitor glibenclamide attenuates high-fat diet and streptozotocin-induced non-alcoholic fatty liver disease in rat: studies on oxidative stress, inflammation, DNA damage and insulin signalling pathway.

51 Asporin levels are low in patients with nonalcoholic fatty liver disease and increase after vitamin E treatment.

52 Alcohol-related liver diseases.

53 Response to "Reply to: 'The decreasing predictive power of MELD in an era of changing etiology of liver disease'".

54 A STUDY OF METABOLIC PARAMETERS IN NON DIABETIC PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE - IMPORTANCE OF DYSLIPIDEMIA.

55 New dual peroxisome proliferator activated receptor agonist - Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: Integrated analysis of the real world evidence

56 Copper modulates sex-specific fructose hepatoxicity in nonalcoholic fatty liver disease (NALFD) Wistar rat models.

57 Adipocytokine Regulation and Antiangiogenic Activity Underlie the Molecular Mechanisms of Therapeutic Effects of Phyllanthus niruri against Non-Alcoholic Fatty Liver Disease.

58 Assessment of liver fibrosis severity using computed tomography-based liver and spleen volumetric indices in patients with chronic liver disease.

59 The association between seizure predisposition and inflammation in a rat model of fatty liver disease.

60 Potential implications of COVID-19 in non-alcoholic fatty liver disease.

61 Effects of green tea or green tea catechin on liver enzymes in healthy individuals and people with nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized clinical trials

62 The effect of green tea extract supplementation on liver enzymes in patients with nonalcoholic fatty liver disease

63 Lack of genetic evidence that fatty liver disease predisposes to COVID-19.

64 Treatment with a novel oleic-acid-dihydroxyamphetamine conjugation ameliorates non-alcoholic fatty liver disease in obese Zucker rats.

65 Pathogenesis, Early Diagnosis, and Therapeutic Management of Alcoholic Liver Disease

66 Pathogenesis, Early Diagnosis, and Therapeutic Management of Alcoholic Liver Disease

67 Alcoholic Liver Disease: Pathogenesis and New Therapeutic Targets

68 Psoralea corylifolia L. Seed Extract Attenuates Nonalcoholic Fatty Liver Disease in High-Fat Diet-Induced Obese Mice

69 Pathogenesis, Early Diagnosis, and Therapeutic Management of Alcoholic Liver Disease

70 Pathogenesis of Alcoholic Liver Disease

71 The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States

72 Alcoholic liver disease: pathogenesis and new targets for therapy

73 THE THERAPEUTIC IMPACT OF PROBIOTICS ON NONALCOHOLIC FATTY LIVER DISEASE IN PEDIATRICS: A SYSTEMATIC REVIEW

74 obese children with metabolic syndrome have 3 times higher risk to have nonalcoholic fatty liver disease compared with those without metabolic syndrome

75 psychometrics of the greek chronic liver disease questionnaire for measuring hrql

76 investigating the deregulation of metabolic tasks via minimum network enrichment analysis (minea) as applied to nonalcoholic fatty liver disease using mouse and human omics data.

77 bariatric surgery and nonalcoholic fatty liver disease: current and potential future treatments

78 ft3/ft4 ratio predicts non-alcoholic fatty liver disease independent of metabolic parameters in patients with euthyroidism and hypothyroidism

79 the state of pancreatobiliary system and intestinal microflora in children with nonalcoholic fatty liver disease

80 how useful are monogenic rodent models for the study of human non-alcoholic fatty liver disease?

81 toll-like receptors in the pathogenesis of alcoholic liver disease

82 plasma hydroxy-metronidazole/ metronidazole ratio in hepatitis c virus-induced liver disease

83 mechanisms and implications of age-related changes in the liver: nonalcoholic fatty liver disease in the elderly

84 stem cell-based therapies for liver diseases: state of the art and new perspectives

85 oxidative stress and the er stress response in a murine model for early-stage alcoholic liver disease

86 associação entre doença hepática gordurosa não alcoólica e marcadores de lesão/função hepática com componentes da síndrome metabólica em indivíduos obesos classe iii association between non-alcoholic fatty liver disease and liver function/injury markers with metabolic syndrome components in class iii obese individuals

87 interactions between bile acids and nuclear receptors and their effects on lipid metabolism and liver diseases

88 misregulation of ppar functioning and its pathogenic consequences associated with nonalcoholic fatty liver disease in human obesity

89 gallstones in patients with chronic liver diseases

90 resveratrol inhibits nonalcoholic fatty liver disease in rats

91 predictors of liver fat and stiffness in non-alcoholic fatty liver disease (nafld) – an 11-year prospective study

92 role of bariatric surgery in treatment of non-alcoholic fatty liver disease

93 the potential role of iron and copper in pediatric obesity and nonalcoholic fatty liver disease

94 postoperative resource utilization and survival among liver transplant recipients with model for end-stage liver disease score ≥40: a retrospective cohort study

95 the relationship between nonalcoholic fatty liver disease and colorectal cancer: the future challenges and outcomes of the metabolic syndrome

96 the model for end-stage liver disease accurately predicts 90-day liver transplant wait-list mortality in atlantic canada

97 diet-induced metabolic hamster model of nonalcoholic fatty liver disease

98 relationship of intestinal microecology with infantile cholestatic liver disease

99 a review of western and traditional chinese medical approaches to managing nonalcoholic fatty liver disease

100 non-invasive investigations for the diagnosis of fontan-associated liver disease in pediatric and adult fontan patients

101 nonalcoholic fatty liver disease: a clinical approach and review

Keyword Connections

Journals

Research Groups

Bibliographies